On-demand treatment with the iron chelator deferasirox is ineffective in preventing blood-induced joint damage in haemophilic mice.

ABSTRACT:

Introduction

Early intervention in the devastating process of haemophilic arthropathy (HA) is highly desirable, but no disease-modifying therapy is currently available. Considering the pivotal role of iron in the development of HA, iron chelation is considered a promising therapeutic approach. A previous study in haemophilic mice demonstrated that treatment with the iron chelator deferasirox (DFX) 8 weeks before joint bleed induction, attenuated cartilage damage upon blood exposure. However, in haemophilia patients this approach is not opportune given the unpredictable occurrence of hemarthroses.

Aim

To evaluate the effectiveness of on-demand DFX treatment, initiated immediately after joint bleed induction.

Methods

A joint bleed was induced in 66 factor VIII-deficient

SUBMITTER: Pulles AE 

PROVIDER: S-EPMC8361985 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature